Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk of SARS-CoV-2 infection in healthcare workers with inflammatory bowel disease: a case-control study.
Amiot A, Bourrier A, Gornet JM, Dewit O, Nancey S, Altwegg R, Abitbol V, Laharie D, Reenaers C, Gagnière C, Buisson A, Nachury M, Viennot S, Vuitton L, Stefanescu C, Marteau P, Bouguen G, Seksik P; GETAID-INFOPRO study group. Amiot A, et al. Among authors: abitbol v. Infect Prev Pract. 2023 Mar;5(1):100267. doi: 10.1016/j.infpip.2022.100267. Epub 2022 Dec 30. Infect Prev Pract. 2023. PMID: 36601289 Free PMC article.
Adalimumab in Biologic-naïve Patients With Crohn's Disease After Resolution of an Intra-abdominal Abscess: A Prospective Study From the GETAID.
Bouhnik Y, Pineton de Chambrun G, Lambert J, Nachury M, Seksik P, Altwegg R, Vuitton L, Stefanescu C, Nancey S, Aubourg A, Serrero M, Filippi J, Desseaux K, Viennot S, Abitbol V, Boualit M, Bourreille A, Giletta C, Buisson A, Roblin X, Dib N, Malamut G, Amiot A, Fumery M, Louis E, Elgharabawy Y, Peyrin-Biroulet L; MICA-GETAID Study Group. Bouhnik Y, et al. Among authors: abitbol v. Clin Gastroenterol Hepatol. 2023 Dec;21(13):3365-3378.e5. doi: 10.1016/j.cgh.2023.01.013. Epub 2023 Jan 31. Clin Gastroenterol Hepatol. 2023. PMID: 36731588 Free article.
Tuberculosis and Immune Reconstitution Inflammatory Syndrome in Patients With Inflammatory Bowel Disease and Anti-TNFα Treatment: Insights From a French Multicenter Study and Systematic Literature Review With Emphasis on Paradoxical Anti-TNFα Resumption.
Amoura A, Frapard T, Treton X, Surgers L, Beaugerie L, Lafaurie M, Gornet JM, Lepeule R, Amiot A, Canouï E, Abitbol V, Froissart A, Vidon M, Nguyen Y, Lefort A, Zarrouk V. Amoura A, et al. Among authors: abitbol v. Open Forum Infect Dis. 2024 Jun 17;11(7):ofae327. doi: 10.1093/ofid/ofae327. eCollection 2024 Jul. Open Forum Infect Dis. 2024. PMID: 38957691 Free PMC article.
Development of a New Index to Assess Small Bowel Inflammation Severity in Crohn's Disease Using Magnetic Resonance Enterography.
Bouhnik Y, Le Berre C, Zappa M, Lewin M, Boudiaf M, Zagdanski AM, Frampas E, Oudjit A, Scotto B, Tissier M, Annet L, Aufort S, Yzet T, Cuilleron M, Baudin G, Abitbol V, Cosnes J, Bourreille A, Mary JY; GETAID CDMRIS Study Group. Bouhnik Y, et al. Among authors: abitbol v. Crohns Colitis 360. 2022 Feb 5;4(1):otac004. doi: 10.1093/crocol/otac004. eCollection 2022 Jan. Crohns Colitis 360. 2022. PMID: 36777552 Free PMC article.
Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID Study.
Fumery M, Caron B, Hébuterne X, Altwegg R, Roblin X, Stefanescu C, Meyer A, Nachury M, Laharie D, Le Berre C, Guillo L, Biron A, Caillo L, Buisson A, Nancey S, Uzzan M, Vuitton L, Gilletta C, Geyl S, Blain A, Kirchgesner J, Ah-Soune P, Duveau N, Vidon M, Abitbol V, Paupard T, Tran-Minh ML, Defrance A, Peyrin-Biroulet L. Fumery M, et al. Among authors: abitbol v. Clin Gastroenterol Hepatol. 2024 Dec;22(12):2451-2458.e1. doi: 10.1016/j.cgh.2024.04.016. Epub 2024 May 9. Clin Gastroenterol Hepatol. 2024. PMID: 38729389
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.
Fumery M, Defrance A, Roblin X, Altwegg R, Caron B, Hébuterne X, Stefanescu C, Meyer A, Nachury M, Laharie D, Nancey S, Le Berre C, Serrero M, Geyl S, Giletta C, Ah-Soune P, Duveau N, Uzzan M, Abitbol V, Biron A, Tran-Minh ML, Paupard T, Vuitton L, Elgharabawy Y, Peyrin-Biroulet L. Fumery M, et al. Among authors: abitbol v. Aliment Pharmacol Ther. 2023 Feb;57(4):426-434. doi: 10.1111/apt.17358. Epub 2022 Dec 19. Aliment Pharmacol Ther. 2023. PMID: 36534763
The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study.
Amiot A, Rahier JF, Baert F, Nahon S, Hart A, Viazis N, Biancone L, Domenech E, Reenears C, Peyrin-Biroulet L, Beaugerie L, Burisch J; I-CARE collaborator group. Amiot A, et al. J Crohns Colitis. 2023 Jan 27;17(1):37-48. doi: 10.1093/ecco-jcc/jjac091. J Crohns Colitis. 2023. PMID: 35767639 Free PMC article.
Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study.
Bouguen G, Gossec L, Abitbol V, Senbel E, Bonnaud G, Roblin X, Bouhnik Y, Nancey S, Mathieu N, Filippi J, Vuitton L, Nahon S, Dellal A, Denis A, Foulley L, Habauzit C, Benkhalifa S, Marotte H. Bouguen G, et al. Among authors: abitbol v. BioDrugs. 2024 Nov;38(6):867-878. doi: 10.1007/s40259-024-00681-2. Epub 2024 Sep 25. BioDrugs. 2024. PMID: 39322802 Free PMC article.
Prevalence and Determinants of Fatigue in Patients with IBD: A Cross-Sectional Survey from the GETAID.
Amiot A, Chaibi S, Bouhnik Y, Serrero M, Filippi J, Roblin X, Bourrier A, Bouguen G, Franchimont D, Savoye G, Buisson A, Louis E, Nancey S, Abitbol V, Reimund JM, DeWit O, Vuitton L, Mathieu N, Peyrin-Biroulet L, Gilletta C, Allez M, Viennot S, Le Berre C, Dib N, Brixi H, Painchart C, Plastaras L, Altwegg R, Fumery M, Caillo L, Laharie D, Nachury M; GETAID-patient experience study group. Amiot A, et al. Among authors: abitbol v. J Crohns Colitis. 2023 Oct 20;17(9):1418-1425. doi: 10.1093/ecco-jcc/jjad060. J Crohns Colitis. 2023. PMID: 36988620 Free article.
155 results